IL33 and acute kidney injury: generated an IL‐2 and IL‐33 fusion cytokine that they termed IL‐233, and which they found increased the recruitment of Tregs into the kidney and protected mice from IRI more efficiently than either cytokine alone.81 Thus, these studies collectively suggest that strategies aimed at enhancing numbers, recruitment and function of endogenous Tregs demonstrates therapeutic potential in AKI, especially as therapies prior to injury in situations where AKI is likely or probable.